Short Interest in Entero Therapeutics, Inc. (NASDAQ:ENTO) Rises By 62.7%

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the target of a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 152,900 shares, an increase of 62.7% from the October 31st total of 94,000 shares. Based on an average daily volume of 395,000 shares, the days-to-cover ratio is presently 0.4 days. Currently, 3.3% of the company’s shares are sold short.

Entero Therapeutics Price Performance

ENTO stock traded up $0.02 during mid-day trading on Friday, hitting $0.47. 25,201 shares of the company were exchanged, compared to its average volume of 174,591. Entero Therapeutics has a 12-month low of $0.19 and a 12-month high of $14.51. The firm’s fifty day simple moving average is $0.52.

Entero Therapeutics (NASDAQ:ENTO) last posted its quarterly earnings data on Monday, October 21st. The company reported ($3.37) earnings per share for the quarter. Sell-side analysts anticipate that Entero Therapeutics will post -1.13 EPS for the current fiscal year.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.